Italian Regulators Cite Two Indian Drugmakers

May 25, 2016

Italian regulatory authorities have cited two Indian drugmakers for dozens of GMP issues, ranging from data security to quality management issues, according to FDAnews Drug Daily Bulletin.

The Italian Medicines Agency recommended that any European regulatory authorities that encounter drugs produced at JP Laboratories’ Maharashtra facility and Krebs Biochemicals & Industries plant in Andhra Pradesh prohibit their use or importation, FDA reported.

The noncompliance report for JP Laboratories found 28 GMP deficiencies at the active substance production plant, nine of which it classified as major. The most significant problems involved quality management issues, data integrity concerns and a lack of production controls.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments